Drugs / VTS-270
VTS-270
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01747135 | Jan 2013 → Mar 2017 | Niemann-Pick disease, type C1 | Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03887533 | Jan 2020 → Oct 2021 | Niemann-Pick disease, type C1 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03471143 | Feb 2019 → Oct 2024 | Niemann-Pick disease type C | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03687476 | May 2020 → Oct 2022 | Niemann-Pick disease type C | Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company | Withdrawn | No outcome recorded Stop: Business |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT03879655 | Dec 2019 → Oct 2021 | Niemann-Pick disease, type C1 | Mandos LLC | Terminated | No outcome recorded Stop: Business |
| Phase 2/3 | NCT04958642 | Dec 2015 → Apr 2022 | Niemann-Pick disease, type C1 | Mandos LLC | Terminated | No outcome recorded Stop: Business |
| Phase 2/3 | NCT02534844 | Oct 2015 → Mar 2018 | Niemann-Pick disease, type C1 | Mandos LLC | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03643562 | Jun 2018 → Nov 2021 | Niemann-Pick disease type C | Mandos LLC | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VTS-270 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03879655 ↗ |
| Known as | 2-hydroxypropyl-beta-cyclodextrin | “Intrathecal 2-hydroxypropyl-beta-cyclodextrin (HPbetaCD, VTS-270) has proven effective in reducing signs and prolonging life in NPC1 animal models” NCT03887533 ↗2“VTS-270 (2-Hydroxypropyl-Beta-Cyclodextrin) will be administered intravenously to specifically target liver disease.” NCT03471143 ↗ “VTS-270 (2-hydroxypropyl beta-cyclodextrin \[HP-β-CD\]) in pediatric participants with age \<4 years.” NCT03687476 ↗ |
| Known as | 2-Hydroxypropyl-β-Cyclodextrin | “Intrathecal 2-Hydroxypropyl-β-Cyclodextrin (HP-β-CD, VTS-270), also known as adrabetadex, has proven effective in reducing the signs and prolonging life in animal models and...” NCT03471143 ↗1“VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Pediatric Subjects Aged < 4 Years With Neurologic Manifestations of Niemann-Pick Type C (NPC) Disease” NCT03687476 ↗ |
| Known as | 2-hydroxypropyl-β-cyclodextrins | “Recently, several drug trials have been implemented to minimize neurodegeneration, including a trial of 2-hydroxypropyl-β-cyclodextrins (VTS-270).” PMID 31187454 ↗ Jul 2019 |
| Known as | Adrabetadex | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04958642 ↗ |
| Known as | HP-β-CD | “Intrathecal 2-Hydroxypropyl-β-Cyclodextrin (HP-β-CD, VTS-270), also known as adrabetadex, has proven effective in reducing the signs and prolonging life in animal models and...” NCT03471143 ↗1“VTS-270 (2-hydroxypropyl beta-cyclodextrin \[HP-β-CD\]) in pediatric participants with age \<4 years.” NCT03687476 ↗ |
| Known as | HPbetaCD | “Intrathecal 2-hydroxypropyl-beta-cyclodextrin (HPbetaCD, VTS-270) has proven effective in reducing signs and prolonging life in NPC1 animal models” NCT03887533 ↗ |
| Route | Intrathecal | “via lumbar intrathecal infusion” NCT02534844 ↗ |